DeutschNewstral
Article
bizjournals.com on 2015-03-30 20:32
FDA panelist confirms conflict of interest following Sarepta drug discussions
Related news
- Why we should care that an FDA panelist forgot to disclose conflicts of interestbizjournals.com
- FSarepta shares surge 90% on FDA approvalft.com
- BSarepta Could Triple on Expedited FDA Approvalbarrons.com
Sarepta Tumbles With Latest Comments from FDAForbes- BSarepta Slammed by FDA, Stock Is Now Intriguingbarrons.com
- BSlim Sarepta Hopes Rest With Top FDA Officialbarrons.com
- Reporter sues FDA for documents related to Sarepta drug approvalbizjournals.com
- MSarepta Therapeutics stock tanks after drug's FDA committee reviewmarketwatch.com
- BSarepta Jumps on FDA Delay but Remains a Buybarrons.com
- MSarepta Therapeutics shares dive on safety issues in FDA databasemarketwatch.com
- MSarepta stock falls on FDA concerns about drugmarketwatch.com
- MSarepta stock drops after Muscular Dystrophy study halted by FDAmarketwatch.com
- Sarepta: FDA Policy Forced AdCom To Vote Against Patients' InterestsForbes
- BSarepta Stock Is Spiking as FDA Reverses Course, Approving Drugbarrons.com
Sarepta Shares Plunge as FDA Raises Doubts About Drugwsj.com- MSarepta stock drops on erroneous adverse event report to FDAmarketwatch.com
- Shares of Cambridge biotech Sarepta crash after harsh FDA reviewbizjournals.com
- MSenate confirms FDA commissionermarketwatch.com
- Sarepta gains after-hours as FDA accepts application for Duchenne drug approvalbizjournals.com